Dopavision, a Berlin, Germany-based company focused on development of digital therapeutics, raised €12M in Series A funding.
The round was led by Seventure Partners with participation from Novartis Pharmaceuticals, Boehringer Ingelheim Venture Fund and Ababax Health.
The company intends to use the funds for the clinical development of MyopiaX, its lead product in childhood myopia, activities to provide innovative digital treatments for children leveraging games, educational or cognitive training applications, and potentially broaden its pipeline to new indications, as well as for building the team.
The company has so far raised €14.7 million in private equity and public grants and is backed by top-tier international investors such as Seventure Partners, Novartis Pharma and Boehringer Ingelheim Venture Fund.
Can't stop reading? This and all news articles are property of their creators, many are not owned or provided by Private Equity Insider. As an event organizer and community platform, we curate content from reliable sources for your suggested reading, and advise you to read the full articles from the referenced authors and sources.